PRDX1 and breast carcinoma: On the other hand, SIRT2 can reduce the activity of peroxiredoxin-1 (Prdx-1) through deacetylation which leads to breast cancer cells accumulating reactive oxygen species (ROS) and becoming less viable (Fiskus et al., 2016).